LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective...